आईएसएसएन: 2381-8727

सूजन, कैंसर और एकीकृत थेरेपी के अंतर्राष्ट्रीय जर्नल

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • शैक्षणिक कुंजी
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • पबलोन्स
  • यूरो पब
  • आईसीएमजेई
इस पृष्ठ को साझा करें


Malizumab Efficacy and Safety in Adult Patients with Wheat-Dependent Exercise-Induced Anaphylaxis: Reduction in Basophil Activation in Vitro and Allergic Reaction to Wheat

Yoko Chin

Background: Anaphylactic shock occurs frequently in patients with wheat-dependent exercise-inducedanaphylaxis (WDEIA), so avoidance of wheat products is advised. The purpose of this study was to assess the efficacyand safety of long-term omalizumab treatment in adult patients with WDEIA [1, 2].
Methods: Twenty adult patients with WDEIA were enrolled in this phase 2 multicenter single-arm trial (UMIN 000019250). All patients received 150-600 mg of omalizumab subcutaneously, and assessments (basophil activation and blood examination) were performed at regular intervals during the administration (0-48 weeks) and observation periods (48–68 weeks). The primary endpoint was the proportion of patients who achieved a basophil activation rate of less than 10% with fractionated wheat preparations, and the secondary endpoint was the proportion of patients who had no allergic reactions after consuming wheat products [3].
Results: During treatment with omalizumab, more than 80% of patients had a basophil activation rate of less than 10% against all fractionated wheat preparations, and 68.8% of patients who met the primary endpoint had no allergic reaction. During the observation period, the proportion of patients with basophil activation rates less than 10% gradually decreased, while the proportion of patients with positive allergic reactions increased gradually and reached a maximum of 46.7%. During the study, no severe adverse events were observed [4].
Conclusions: Long-term omalizumab treatment is safe and effective for adult patients with WDEIA, as measured by basophil activation rate with wheat allergens and allergic reactions after removing wheat restrictions. This, however, is insufficient to achieve desensitisation.